

Mohammad Azam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3841420/publications.pdf>

Version: 2024-02-01

22
papers

314
citations

1163117
8
h-index

1199594
12
g-index

22
all docs

22
docs citations

22
times ranked

678
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia. <i>Nature Medicine</i> , 2017, 23, 472-482.	30.7	75
2	Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK. <i>Clinical Cancer Research</i> , 2019, 25, 4117-4127.	7.0	53
3	Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance. <i>Scientific Reports</i> , 2015, 5, 14538.	3.3	45
4	Expansion of EPOR-negative macrophages besides erythroblasts by elevated EPOR signaling in erythrocytosis mouse models. <i>Haematologica</i> , 2018, 103, 40-50.	3.5	30
5	Phospho serine and threonine analysis of normal and mutated granulocyte colony stimulating factor receptors. <i>Scientific Data</i> , 2019, 6, 21.	5.3	29
6	The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes. <i>Haematologica</i> , 2019, 104, 485-496.	3.5	25
7	Adaptive responses to <i>mTOR</i> gene targeting in hematopoietic stem cells reveal a proliferative mechanism evasive to mTOR inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	19
8	SWATH-Proteomics of Ibrutinib's Action in Myeloid Leukemia Initiating Mutated <i>CSFR</i> Signaling. <i>Proteomics - Clinical Applications</i> , 2020, 14, e1900144.	1.6	16
9	Momelotinib is a highly potent inhibitor of FLT3-mutant AML. <i>Blood Advances</i> , 2022, 6, 1186-1192.	5.2	10
10	MEK/ERK addiction in CNL/aCML. <i>Oncotarget</i> , 2017, 8, 99215-99216.	1.8	5
11	A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors. <i>Journal of Visualized Experiments</i> , 2014, , .	0.3	3
12	Compound Heterozygosity of Two Novel JAK2 Mutations in Hereditary Essential Thrombocythemia Implicates Important Monomer-Monomer Interactions in Thrombopoiesis Signaling. <i>Blood</i> , 2016, 128, 3137-3137.	1.4	2
13	PLaCatinG AML1-ETO. <i>Blood</i> , 2022, 139, 959-961.	1.4	2
14	Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence. <i>Journal of Visualized Experiments</i> , 2019, , .	0.3	0
15	Mechanisms of Drug Resistance Against JAK2 Inhibitors. <i>Blood</i> , 2011, 118, 1426-1426.	1.4	0
16	Targeting the Genetic Resistance of JAK2 and BCR/ABL by TG101348. <i>Blood</i> , 2012, 120, 3765-3765.	1.4	0
17	Overcoming Drug Resistance Of FLT3-ITD By SAR302503. <i>Blood</i> , 2013, 122, 5023-5023.	1.4	0
18	A Common Signaling Node Constitute Non-Oncogene Addiction in Kinase Driven Leukemia:Mechanism of Oncogne Addiction in CML. <i>Blood</i> , 2016, 128, 3056-3056.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Enhanced MAPK Signaling Constitute Non-Oncogene Addiction in CSF3R Induced Leukemia. Blood, 2016, 128, 632-632.	1.4	0
20	Loss of DUSP1 Is Synthetic Lethal to JAK2V617F. Blood, 2018, 132, 51-51.	1.4	0
21	DUSP1 Confers Oncogene Dependence in CSF3R Induced Leukemia. Blood, 2018, 132, 1341-1341.	1.4	0
22	Momelotinib Is a Highly Potent Inhibitor of FLT3-Mutant AML. Blood, 2021, 138, 206-206.	1.4	0